Compare Firy Inc. (FIRY) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Firy Inc. vs Novartis AG — how do they compare? Firy Inc. trades at $10.31 (market cap $163.57M), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 1823× Firy Inc.'s market cap, and Novartis AG pays a 3.02% dividend while Firy Inc. pays none. Which is the better fit depends on your goals.
| FIRY | NVS | |
|---|---|---|
Market Cap | $163.57M | $298.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $12.45 | $168.62 |
52-Week Low | $2.28 | $118.55 |
Enterprise Value | $107.24M | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIRY stock trades at $10.45, up 4.5% today, with a bullish technical signal from moving averages. The company shows improving revenue trends ($104.5M in 2025, projected to $112M in 2026) but continues to post significant losses (-$70.4M net income). Recent developments include a successful $719M legal victory and corporate rebranding from Skillz Inc. Analyst sentiment is mixed with 20% buy, 60% hold, and 20% sell ratings.
While technical indicators suggest near-term upside potential, fundamental challenges persist with negative profitability metrics and cash burn. The stock presents speculative appeal based on legal wins and revenue stabilization, but requires careful risk management given ongoing losses and negative cash flow trends.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
